TY - JOUR T1 - Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P759 AU - Svenja Ehlers-Tenenbaum AU - Ute Oltmanns AU - Karin Palmowski AU - Thomas Muley AU - Miriam Schaaf AU - Arne Warth AU - Philipp A. Schnabel AU - Claus P. Heussel AU - Felix J.F. Herth AU - Michael Kreuter Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P759.abstract N2 - Introduction: Comorbidities have a significant influence on the clinical course of IPF. However, their prognostic impact is not fully understood.Methods: Patients with IPF were selected from the database of our tertiary referral center for interstitial lung diseases and reviewed for details on patient comorbidities, their frequency per patient and overall survival data. .Results: Between 1/2004-12/2011, 272 IPF patients were identified: 75% male, 74% ex-/smokers (median 30 PY), medians: age 70 years, vital capacity 72% predicted, diffusion capacity 44% predicted. Comorbidities were found in 88% of patients and the number of comorbidities per patient was 1 in 19%, 2 in 19%, 3 in 21% and >3 in 29%. In a comorbidom analysis (n=107) after a median follow up of 56 months, median survival was 42 (95% CI 23-61) months. Median survival was significantly longer in patients with ≤ 3 comorbidities (n=70, 60 months) compared to patients with 4 comorbidities (n=37, 25 months, p=0,03). In a multivariate analysis, survival was significantly influenced by lung cancer (HR 5.7, p<0.0001), depression (HR 4.4, p=0.007) and cardiovascular diseases (HR 2.32, p=0.015). Coronary artery disease (univariate, p=0.047) and diabetes mellitus (HR 1.84, p=0.067) were of borderline significance.Conclusion: Comorbidities are frequent in IPF patients and their cumulative incidence impacts on survival, especially lung cancer and depression. Future research should focus on improved screening and treatment of comorbidities in these severely compromised patients and assess the potential impact on quality of life and survival rates. ER -